Agitation clinical trials at University of California Health
1 research study open to eligible people
Showing trials for
Masupirdine for the Treatment of Agitation in Dementia of the Alzheimer's Type
open to eligible people ages 50-90
This study will be conducted to evaluate the efficacy, safety, tolerability, and pharmacokinetics of masupirdine compared to placebo for the treatment of agitation in participants with dementia of the Alzheimer's type.
Our lead scientists for Agitation research studies include Pauline Wu, DO.